Neurofit Presents AI Technology Research on Quantitative Dementia Analysis Using Brain Imaging at 'AOCR&KCR 2022'

[Asia Economy Reporter Jang Hyowon] Neurofit, a specialized company in AI solutions for brain disease imaging, announced on the 22nd that it participated in the 20th Asia Oceania Congress of Radiology (AOCR 2022) and the 78th Korean Congress of Radiology (KCR 2022), presenting research results on AI technology for quantitative analysis of dementia based on brain imaging.

At the AI stage presentation of this academic conference, Donghyun Kim, CTO of Neurofit, delivered a presentation titled "Quantitative Approach for Prognosis/Staging/Analysis in Dementia Study."

Alzheimer's disease, a representative type of dementia, is nearly impossible to recover cognitive function to pre-onset levels once it develops. Alzheimer's disease is a condition where prevention and early detection are most crucial. Recently, with advances in brain imaging analysis technology, various attempts have been made to predict the likelihood of onset before Alzheimer's disease develops through MRI (Magnetic Resonance Imaging), PET (Positron Emission Tomography) imaging, and others.

CTO Donghyun Kim focused on introducing brain imaging analysis technologies that have been gaining importance in recent dementia research. Neurofit has developed brain imaging analysis technology that provides quantitative values of neurodegeneration, vascular neuropathology, amyloid-beta protein, tau protein, and FDG (fluorodeoxyglucose) visible in MRI T1, T2 FLAIR, SWI images, as well as amyloid-PET and FDG-PET images.

Neurofit expects that by quantitatively measuring Alzheimer's disease biomarkers and subdividing the stages, early detection and prevention of Alzheimer's disease will be possible. In 2020, Neurofit was selected as an executing institution for the government-led Dementia Overcoming Research and Development Project and is conducting the "ATNV Project," a brain imaging-based dementia diagnosis and prognosis prediction technology task, jointly with the Catholic University Yeouido St. Mary's Hospital.

CTO Donghyun Kim stated, "The prognostic indicators for Alzheimer's disease differ depending on the type of brain imaging. By utilizing AI technology to quantify each indicator and comprehensively analyze them, it will help to further subdivide the stages of Alzheimer's disease and enable earlier diagnosis than before."

At this event, Neurofit showcased its core products from the ATNV project: the neurodegeneration imaging analysis software "Neurophet AQUA" and the PET image automatic analysis software "Neurophet SCALE PET."

Neurofit CEO Jungil Bin said, "Through this event, we met leading radiologists and medical imaging experts worldwide and introduced Neurofit's core products, receiving great interest and response. Neurofit is also pursuing research and development for various brain diseases such as stroke, mild cognitive impairment, and depression, and we will continue to strive to become a leading company in the brain disease imaging AI solution field."

Meanwhile, the "AOCR 2022 & KCR 2022" event, which started on the 20th, will be held at COEX, Seoul, until the 24th.

This content was produced with the assistance of AI translation services.